Skip to main content

Advertisement

Table 2 Immunomodulatory effect of nilotinib versus placebo treatment on synovial histopathology

From: A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis

Marker Nilotinib Placebo
Week 0 Week 12 Week 0 Week 12
CD68 lining 1.7 (1.7–3.0) 0.3 (0.0–2.0) 2.8 (1.2–3.0) 2.3 (1.7–3.0)
CD68 sublining 2.0 (1.3–2.3) 0.0 (0.0–1.3) 2.0 (1.0–3.0) 1.7 (1.3–2.0)
CD163 lining 2.7 (2.0–2.7) 0.7 (0.0–2.0) 2.8 (0.7–3.0) 2.7 (2.7–2.7)
CD163 sublining 2.3 (2.3–2.7) 1.3 (0.3–2.0) 2.3 (1.4–3.0) 2.3 (2.3–2.3)
c-Kit 1.0 (0.3–2.3) 0.0 (0.0–0.7) 0.0 (0.0–0.8) 1.3 (0.3–2.3)
  1. Values are the median (IQR) assessed on a semiquantitative scale